In the annual report the are 4 things listed - expand ph 2 study enrollment globally - expand BioMuse study up to 20 patients - proof of concept study for PD - generate new IND candidates (drug discovery)
2 first ones are clearly almost done, now 10 hospitals are recruiting. The target of 30 places is IMO too high to get 20+20+20 patients but to start proof of concept study for PD may need all of 30 of them. For the ph 2 I would think 15 hospitals will be enough, an average of 4 patients in each hospital will do, IMO.
So it looks like proof of concept study for PD is the next study, but for that the results of the primate study are needed to get the right dosing (?) They may not to publish these results but I hope they will, at least as a conference paper. It has been 2 years since they got the money for the animals. The proof of concept study could be the start of ph 3 in PD.
ATH Price at posting:
0.9¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)